{"id":109245,"date":"2026-06-06T07:54:01","date_gmt":"2026-06-06T07:54:01","guid":{"rendered":"https:\/\/pakistaninewspaperlist.com\/news\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/"},"modified":"2026-06-06T07:54:01","modified_gmt":"2026-06-06T07:54:01","slug":"oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/oban-biopharma-announces-presentation-of-late-breaking-abstract-at-ada-2026-highlighting-obt-676-a-first-in-class-small-molecule-combining-dual-amylin-and-calcitonin-receptor-full-agonism-dacra-wit\/","title":{"rendered":"Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism (DACRA) with GLP-1, GIP and Glucagon (Triple-G) Receptor Partial Agonism"},"content":{"rendered":"
\n

STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) — Oban BioPharma today announced that preclinical data for\u00a0OBT-676<\/strong>, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5th<\/sup>-8th<\/sup> in New Orleans, LA. The study characterizes OBT-676 as a new molecular entity that achieves potent full agonism at the amylin and calcitonin receptors (DACRA) while simultaneously delivering partial agonism across the GLP-1, GIP, and glucagon (Triple-G) pathways. OBT-676 demonstrated significant reduction in food intake and adipose-selective weight loss in the industry-standard rat diet-induced obesity (DIO) model.<\/p>\n

“The OBT-676 data being presented at ADA underscores a significant leap in the evolution of small molecule, multimodal metabolic therapies\u201d, said Derek Chalmers, Ph.D., D.Sc., Co-Founder & CEO of Oban BioPharma. \u201cWith OBT-676, and a series of related analogs, we have moved beyond incretin receptor-focused injectable peptides to an oral small molecule class targeting multiple metabolic systems, encompassing potent amylin receptor activation paired with balanced incretin and glucagon receptor signaling. These DACRA\/Triple-G small molecule compounds have the potential of shifting the treatment goal for millions of patients managing chronic metabolic diseases from simple weight reduction to high-quality metabolic restoration, prioritizing adipose-biased weight loss and superior tolerability with an orally available drug.\u201d<\/p>\n

Presentation Details:<\/strong><\/p>\n

Title:<\/strong> OBT-676, a Novel Oral Small Molecule Combining Full DACRA Activity with \u201cTriple-G\u201d Partial Agonism for the Treatment of Metabolic Diseases
Poster #:<\/strong> LB-2848
Session:<\/strong> Late Breaking
Date:<\/strong> Sunday June 8th
<\/sup>Time:<\/strong> 12.30pm-1.30pm CT
Summary<\/strong>: OBT-676 exhibited picomolar potency and full agonism at AMY-1, AMY-3, and calcitonin receptors along with calibrated partial agonism at GLP-1, GIP and Glucagon receptors. Administration of OBT-676 in diet-induced obese rats resulted in significant, dose-dependent reductions in food intake and adipose-selective weight loss.
2848-LP ADA Poster Final 29May26 QR.pdf<\/a><\/p>\n

About Oban BioPharma<\/strong><\/p>\n

Oban BioPharma is a privately held biotechnology company focused on the development of novel oral small molecule GPCR-targeted therapeutics for metabolic and CNS diseases. Oban combines the power of computational structural and chemotype analysis with AI-based \u201cdruggability\u201d filters to create a faster, more efficient path to new medicines.<\/p>\n

For additional information please visit: https:\/\/obanbiopharma.com<\/a><\/p>\n

Contact: info@obanbiopharma.com<\/p>\n

\n <\/div>\n","protected":false},"excerpt":{"rendered":"

STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) — Oban BioPharma today announced that preclinical data for\u00a0OBT-676, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5th-8th in New Orleans, LA. […]<\/p>\n","protected":false},"author":2,"featured_media":109246,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/2164705c-716b-4084-b502-348231ad618e","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-109245","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t